PharmChem (PharmChem) EBIT : $0.30 Mil (TTM As of Sep. 2023)

View and export this data going back to 2003. Start your Free Trial

What is PharmChem EBIT?

PharmChem's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $0.30 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.30 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PharmChem's annualized ROC % for the quarter that ended in Sep. 2023 was 123.41%. PharmChem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 262.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PharmChem's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 2.29%.

PharmChem EBIT Historical Data

The historical data trend for PharmChem's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmChem EBIT Chart

PharmChem Annual Data

Trend

Dec93

Dec94

Dec95

Dec96

Dec97

Dec98

Dec99

Dec00

Dec01

Dec02

EBIT

Get a 7-Day Free Trial

1.20

2.75

0.80

-8.10

-0.78

PharmChem Quarterly Data
	Jun99	Sep99	Dec99	Mar00	Jun00	Sep00	Dec00	Mar01	Jun01	Sep01	Dec01	Mar02	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Sep22	Sep23
EBIT	Get a 7-Day Free Trial															-0.59	-0.42	-0.32	0.29	0.30

Competitive Comparison of PharmChem's EBIT

For the Diagnostics & Research subindustry, PharmChem's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmChem's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PharmChem's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PharmChem's EV-to-EBIT falls into.

PharmChem EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30 Mil.

PharmChem (OTCPK:PCHM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PharmChem's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2022 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	1.212 * ( 1 - 31.17% )	/	( (0	+	0.676)	/ 1 )
=	0.8342196	/	0.676
=	123.41 %

where

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.252	-	0.48	-	( 2.096	-	max(0, 0.683	-	3.251	+	2.096	))
=	0.676

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

PharmChem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2022		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1.212	/	( ( (0 + max(0, 0))	+	(0 + max(0.461, 0)) )	/	1 )
=	1.212	/	( ( 0	+	0.461 )	/	1 )
=	1.212	/	0.461
=	262.91 %

where Working Capital is:

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.717	+	0.295	+	0.132)	-	(0.48	+	0.203	+	0)
=	0.461

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PharmChem's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	0.303	/	13.246
	=	2.29 %

PharmChem EBIT Related Terms

Thank you for viewing the detailed overview of PharmChem's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmChem (PharmChem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PharmChem Inc (OTCPK:PCHM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2411 E. Loop 820 N, Fort Worth, TX, USA, 76118

Website

https://www.pharmchek.com

PharmChem Inc is engaged in selling and distributing of the PharmChek Sweat Patch Device. PharmChek is a system that uses sweat to detect the presence of illegal drugs. It consists of a transparent polyurethane outer covering, a small absorbent pad, and a release liner. Geographically the activities are carried out throughout the United States.

Executives

Alto Investors Palo	10 percent owner	470 UNIVERSITY AVENUE, PALO ALTO CA 94301
Micro Cap Partners Lp	10 percent owner

PharmChem (PharmChem) Headlines

From GuruFocus

PharmChem (PCHM) Announces Response To Opposition

By PRNewswire PRNewswire • 08-11-2021